Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis
- 31 March 2000
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 22 (3), 362-370
- https://doi.org/10.1016/s0149-2918(00)80041-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A Metaregression Analysis of the Dose-Response Effect of Aspirin on StrokeArchives of Internal Medicine, 1999
- Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Comprehensive Decision ModelJournal of Clinical Epidemiology, 1999
- Antithrombotic and Thrombolytic Therapy for Ischemic StrokeChest, 1998
- Cost-effectiveness of tissue plasminogen activator for acute ischemic strokeNeurology, 1998
- The Greater Cincinnati/Northern Kentucky Stroke StudyStroke, 1998
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of strokeJournal of the Neurological Sciences, 1996
- Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillationPublished by American Medical Association (AMA) ,1995
- Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.Stroke, 1994
- Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project.Stroke, 1994